Agilent Technologies Inc. (NYSE:A) is one of them The stock on which Jim Cramer expressed his opinion. A caller asked if the stock would ever come back, and here’s what Cramer had to say in response:
You know, they test and measure so much that is biotech. It’s almost like Danaher, which has stopped working. Danaher, Agilent, I don’t think you need it.
Stock market chart. Photo by Arturo A in Pixels
Agilent Technologies, Inc. (NYSE:A) provides instruments, software, and services for life sciences, diagnostics, and chemical analysis, including chromatography, spectroscopy, genomics, and laboratory automation solutions. Cramer discussed the stock’s pre- and post-COVID performance through December 1, 2025, as he said:
Last week, just before Thanksgiving, I had the opportunity to speak with Agilent Technologies. It is an arms dealer to the life sciences industry. Not long ago, this stock, known as the letter A for its stock symbol, was a major growth vehicle. In the decade before COVID, the Agilent chart was just a thing of beauty. Then, when the pandemic broke out, the stock got even higher, and since the pandemic subsided, things got worse for it but also for the entire industry. The life sciences companies had all the equipment they needed, so the entire group spent years in the doghouse.
While we accept A’s potential as an investment, we believe some AI stocks offer higher potential and lower risk. If you’re looking for the most undervalued AI stocks that stand to benefit significantly from Trump-era tariffs and the offshore trend, check out our free report Best short-term AI stocks.
Read more: 30 stocks that should double in 3 years and 11 Secret AI Stocks to Buy Right Now.
Disclosure: None. Follow the inside port on Google News.
